UX143, BPS804 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 274 | Osteogenesis Imperfecta | 1 |
274. Osteogenesis Imperfecta
Clinical trials : 91 / Drugs : 101 - (DrugBank : 20) / Drug target genes : 11 - Drug target pathways : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-006597-23-FR (EUCTR) | 04/05/2022 | A study to test product setrusumab in subjects with brittle bone syndrome. | A Randomized, Double-Blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta. | Osteogenesis imperfecta (OI) MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: Setrusumab Product Code: BPS804, UX143 INN or Proposed INN: SETRUSUMAB Other descriptive name: UX143, BPS804 | Ultragenyx Pharmaceutical Inc. | NULL | NA | Female: yes Male: yes | 231 | Phase 2;Phase 3 | United States;France;Canada;Argentina;Denmark;Australia;Germany;United Kingdom;Italy |